Rosetta Genomics has introduced a new diagnostic cancer test, the miReview Meso. According to the company, the miReview Meso test is able to differentiate between mesothelioma and other carcinomas in the lung. The miReview Meso test is available commercially through Rosetta Genomics’ CLIA certified lab in Philadelphia, Pennsylvania.
Harvey Pass, chief of thoracic surgery and thoracic oncology at the New York University Langone Medical Center, said I am very excited to finally see a molecularly based test that can objectively differentiate mesothelioma from several types of carcinomas in the lung with such high level of accuracy. Ruling out mesothelioma from lung cancer for individuals that were exposed to asbestos can be difficult and challenging. I am sure that this test will become an important tool for both oncologists and pathologists in obtaining the right diagnosis in these patients.
Rosetta Genomics expects to perform approximately 2,000 tests during 2009.